Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival.
Isofol’s Board of Directors has resolved on a fully guaranteed new share issue with preferential rights for Isofol’s existing shareholders. Through the transaction, the company will receive approximately SEK 150 million before transaction costs. The Board of Directors is also authorized to carry out a conditional directed share issue with deviation from the shareholders’ preferential rights of up to approximately SEK 30 million. The purpose of the rights offering and the potential directed share issue is to ensure the continued and successful development of the company, in accordance with its business plan and strategy.